PDF(Pubmed)
Abstract：
With the lifting of COVID-19 non-pharmaceutical interventions, the resurgence of common viral respiratory infections was recorded in several countries worldwide. It facilitates viral co-infection, further burdens the already over-stretched healthcare systems. Racing to find co-infection-associated efficacy therapeutic agents need to be rapidly established. However, it has encountered numerous challenges that necessitate careful investigation. Here, we introduce a potential recombinant minibody-associated treatment, 3D8 single chain variable fragment (scFv), which has been developed as a broad-spectrum antiviral drug that acts via its nucleic acid catalytic and cell penetration abilities. In this research, we demonstrated that 3D8 scFv exerted antiviral activity simultaneously against both influenza A viruses (IAVs) and coronaviruses in three established co-infection models comprising two types of coronaviruses [beta coronavirus-human coronavirus OC43 (hCoV-OC43) and alpha coronavirus-porcine epidemic diarrhea virus (PEDV)] in Vero E6 cells, two IAVs [A/Puerto Rico/8/1934 H1N1 (H1N1/PR8) and A/X-31 (H3N2/X-31)] in MDCK cells, and a combination of coronavirus and IAV (hCoV-OC43 and adapted-H1N1) in Vero E6 cells by a statistically significant reduction in viral gene expression, proteins level, and approximately around 85%, 65%, and 80% of the progeny of \'hCoV-OC43-PEDV\', \'H1N1/PR8-H3N2/X-31\', and \'hCoV-OC43-adapted-H1N1\', respectively, were decimated in the presence of 3D8 scFv. Taken together, we propose that 3D8 scFv is a promising broad-spectrum drug for treatment against RNA viruses in co-infection.
摘要：
随着COVID-19非药物干预措施的解除，全球有几个国家记录了常见病毒性呼吸道感染的死灰复燃.它促进病毒共感染，进一步负担已经过度紧张的医疗保健系统。需要迅速建立寻找与共感染相关的功效治疗剂的竞赛。然而,它遇到了许多挑战，需要仔细调查。这里,我们介绍了一种潜在的重组微型抗体相关治疗方法，3D8单链可变片段(scFv),它已被开发为一种广谱抗病毒药物，通过其核酸催化和细胞渗透能力发挥作用。在这项研究中,我们证明了3D8scFv在三种已建立的共感染模型中同时对甲型流感病毒（IAV）和冠状病毒具有抗病毒活性，该模型包括两种类型的冠状病毒[β冠状病毒-人冠状病毒OC43（hCoV-OC43）和α冠状病毒-猪流行性腹泻病毒（PEDV）]在VeroE6细胞中，MDCK细胞中的两个IAV[A/波多黎各/8/1934H1N1(H1N1/PR8)和A/X-31(H3N2/X-31)]，以及VeroE6细胞中冠状病毒和IAV（hCoV-OC43和适应的H1N1）的组合，通过病毒基因表达的统计学显着降低，蛋白质水平，大约85%左右，65%,和80%的“hCoV-OC43-PEDV”后代，\'H1N1/PR8-H3N2/X-31\',和\'hCoV-OC43-adapted-H1N1\'，分别,在3D8scFv的存在下被抽取。一起来看,我们认为3D8scFv是一种有前途的广谱药物，用于治疗共感染的RNA病毒。
